Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8775141 | 1.00 | — | — | |
| SCHEMBL10829091 | 1.00 | ALOX15 (0.44) | ALOX15ALDH1A1PKMACE2POLB | |
| SCHEMBL9119982 | 0.90 | ALOX15 (0.38) | ALOX15ALDH1A1PKM | |
| SCHEMBL3299885 | 0.87 | PAOX (0.40) | ALOX15KDM4E | |
| Hydrochloric Acid SCHEMBL9391723 | 0.87 | ALOX15 (0.36) | ALOX15ALDH1A1PKM | |
| SCHEMBL12098084 | 0.86 | — | — | |
| SCHEMBL1346805 | 0.86 | — | — | |
| SCHEMBL5314835 | 0.85 | ALDH1A1 (0.52) | ALDH1A1PKMPOLBHRH3KDM4E | |
| SCHEMBL686085 | 0.85 | DRD2 (0.43) | ALOX15 | |
| SCHEMBL15183069 | 0.85 | SIGMAR1 (0.37) | ALOX15ALDH1A1PKMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005879-A | Modified GRPR antagonist peptides for cancer imaging and treatment | 慕尼黑工业大学 | 2026-05-12 | — | — | CN | claimed |
| EP-4719494-A2 | USES OF PSMA-TARGETING AND TSPO-TARGETING COMPOUNDS FOR EVALUATION OF INJURIES IN THE PERIPHERAL NERVOUS SYSTEM | The Johns Hopkins University (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4590345-A2 | HIGH-PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Nuclidium AG (CH) | 2025-07-30 | — | — | EP | claimed |
| WO-2024250006-A2 | USES OF PSMA-TARGETING AND TSPO-TARGETING COMPOUNDS FOR EVALUATION OF INJURIES IN THE PERIPHERAL NERVOUS SYSTEM | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-12-05 | — | — | WO | claimed |
| WO-2024064969-A2 | HIGH-PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2024-03-28 | — | — | WO | claimed |
| EP-4313049-A1 | HETEROBIVALENT AND HOMOBIVALENT AGENTS TARGETING FIBROBLAST ACTIVATION PROTEIN ALPHA AND/OR PROSTATE-SPECIFIC MEMBRANE ANTIGEN | The Johns Hopkins University (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117460528-A | anti-CLDN 18.2 antibody conjugates | 苏州创胜医药集团有限公司 | 2024-01-26 | — | — | CN | claimed |
| WO-2024007034-A2 | DENDRIMER-DELIVERED ALPHA-PARTICLE RADIOTHERAPY FOR TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS IN THE BRAIN | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-01-04 | — | — | WO | claimed |
| EP-4294441-A1 | ANTI-CLDN18.2 ANTIBODY CONJUGATES | Suzhou Transcenta Therapeutics Co., Ltd. (CN) | 2023-12-27 | — | — | EP | claimed |
| WO-2023245169-A1 | ANTIMICROBIAL PEPTIDE COMBINATIONS | Vestaron Corporation (US) | 2023-12-21 | — | — | WO | claimed |
| WO-2023163553-A1 | MITOCHONDRIA-TARGETING CANCER THERAPEUTIC COMPOSITION | 서울대학교산학협력단 | 2023-08-31 | — | — | WO | claimed |
| WO-2022212958-A1 | HETEROBIVALENT AND HOMOBIVALENT AGENTS TARGETING FIBROBLAST ACTIVATION PROTEIN ALPHA AND/OR PROSTATE-SPECIFIC MEMBRANE ANTIGEN | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-10-06 | — | — | WO | claimed |
| WO-2022174809-A1 | ANTI-CLDN18.2 ANTIBODY CONJUGATES | Suzhou Transcenta Therapeutics Co., Ltd. (CN) | 2022-08-25 | — | — | WO | claimed |
| CN-122005879-A | Modified GRPR antagonist peptides for cancer imaging and treatment | 慕尼黑工业大学 | 2026-05-12 | — | — | CN | disclosed |
| EP-4727957-A2 | PVD1 VARIANT POLYPEPTIDES FOR PEST CONTROL | Vestaron Corporation (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4719494-A2 | USES OF PSMA-TARGETING AND TSPO-TARGETING COMPOUNDS FOR EVALUATION OF INJURIES IN THE PERIPHERAL NERVOUS SYSTEM | The Johns Hopkins University (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20110092806-A1 | Compounds Comprising a Biological Target Recognizing Part, Coupled to a Signal Part Capable of Complexing Gallium | GUEREBET (FR) | 2011-04-21 | — | — | US | disclosed |
| WO-2010066051-A1 | THIOL-NOTA DERIVATIVES FOR KIT 68GA RADIOLABELING | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2010-06-17 | — | — | WO | disclosed |
| EP-1940841-A2 | COMPOUNDS COMPRISING A BIOLOGICAL TARGET RECOGNIZING PART, COUPLED TO A SIGNAL PART CAPABLE OF COMPLEXING GALLIUM | GUERBET (FR) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007042504-A2 | COMPOUNDS COMPRISING A BIOLOGICAL TARGET RECOGNIZING PART, COUPLED TO A SIGNAL PART CAPABLE OF COMPLEXING GALLIUM | GUERBET (FR) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092806-A1 | Compounds Comprising a Biological Target Recognizing Part, Coupled to a Signal Part Capable of Complexing Gallium | KLK3, IGF1R, GIPR | ALOX15 4663/4885ALDH1A1 4744/4885PKM 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.